Most of what circulates about Amanita online is rooted in folklore, anecdote, or borrowed from the psilocybin conversation. The science on Amanita muscaria is still young, but the science on muscimol, its main active compound, is not. Muscimol has been studied for decades as a research tool for understanding the GABA system (the main inhibitory system in the body), and that body of work tells us quite a lot about how this mushroom can benefit our mental and physical wellbeing.

Why Muscimol Research Matters for Amanita Users

Muscimol appears in over 52,000 papers on Google Scholar. This is because it is one of the most direct activators of the GABAa receptor ever identified. Unlike synthetic GABA, it is able to cross the blood-brain barrier (a specialized wall of cells that protect the brain & nervous system from the rest of the body). It is also able to bind to the GABAa receptor with greater affinity than our own endogenous GABA, allowing it to activate the receptor for several hours. This makes muscimol an ideal research compound for studying the GABA system. 

What makes muscimol especially interesting is where it binds. Most GABAergic substances (like alcohol, benzodiazepines & kava) bind at the allosteric site, a side entrance on the receptor that amplifies GABA’s effect indirectly. Muscimol binds at the orthosteric site, the main binding pocket where our own endogenous GABA docks. These create a fundamentally different cascade of effects, which is why muscimol produces effects that are more akin to a well functioning GABA system. It is also why muscimol can be taken daily without the tolerance buildup or dependency risks associated with pharmaceutical GABAergics

 

Why Study the GABA System?

In general, GABA is the system responsible for slowing things down, creating calm, and pulling the nervous system out of overdrive. In a modern world that keeps us in a near-constant state of stress & inflammation, it is one of the most taxed systems in the body. Dysfunction here has been implicated in anxiety, insomnia, mood disorders, pain, epilepsy, and neurodegeneration.

Muscimol research, by extension, is research into all of these. And what makes this directly relevant to Amanita users is that decarboxylated (fully processed) preparations deliver the same compound being studied in these labs, just at much lower and more gradual doses than most research protocols. The translation is not perfectly direct, but it is enough to establish a basic understanding of the mechanism behind muscimol and Amanita.

 

The Research Landscape

Interest in Amanita has been steadily growing over the past few years. Google searches rose 114% between 2022 and 2023 alone. With that interest has come a wave of new research: a 2023 systematic review covering 22 studies found muscimol effective at reducing neuropathic pain with effects appearing within 15 minutes, a 2023 paper in Frontiers in Pharmacology examined Amanita extract’s effect on human brain immune cells for the first time and a 2024 animal study found muscimol reduced anxiety and depression-related behaviors. The research is pointing somewhere meaningful and I am confident that research will only continue to grow in size and quality over the coming years. 

For now, I've collected the most significant and interesting studies that we do have on muscimol & Amanita muscaria to better understand the effects many people experience while microdosing this wonderful mushroom. I will do my best to update this page as more studies get published.

 

Study Library

Anxiety & Stress

Muscimol and conditioned fear (Bhaskaran & Bhatt, 2006 — Journal of Neuroscience)
Muscimol reduced conditioned fear responses in animal models by inhibiting activity in the brain regions responsible for encoding emotional memory. Particularly relevant for anxiety rooted in past experience, not just situational stress.
→ View study

GABAergic botanicals and anxiety (Savage et al., 2017 — Phytotherapy Research)
A systematic review of GABA-modulating plants found consistent evidence that compounds acting on the GABAa receptor reduce anxiety in both animal and human studies. Muscimol works through this same mechanism.
→ View study

Muscimol and anxiety/depression behaviors ((Ferreira-Chamorro et al., 2024 — Neuropharmacology)
Microinjection of muscimol into specific limbic brain regions reduced anxiety and depressive behaviors in rodents, adding specificity to how GABA modulation translates into mood outcomes.

→ View study

Muscimol and GABAa receptor binding (Sigel & Steinmann, 2012 — Journal of Biological Chemistry)
A detailed overview of muscimol's orthosteric action on the GABAa receptor, covering its role in quieting overactive neural firing and restoring inhibitory balance across the central nervous system.
→ View study

Low GABA and emotional regulation (European Journal of Pain, 2021)
Research shows that low levels of GABA make it significantly harder for people to regulate negative emotions including anxiety, fear, and depression. This adds direct human evidence to the mechanistic case for why restoring GABAergic tone — which muscimol supports — has such a meaningful impact on emotional wellbeing.
→ View study

 

Sleep

Muscimol and slow wave sleep (Lancel et al., 1999 — Sleep)
Muscimol increased the duration and depth of slow wave sleep, the most physically restorative stage, while reducing wakefulness and improving sleep consolidation in animal models.
→ View study

 

Muscimol and REM sleep (Rouhani et al., 1998 — Alcohol)
Muscimol increased the percentage of REM sleep while decreasing active wakefulness in animal models, adding to evidence that muscimol supports a fuller, more complete sleep architecture rather than simply sedating.
→ View study

 

Muscimol and sleep spindles (Ayoub et al., 2013 — PLoS Biology)
Muscimol increased sleep spindle density, a marker of restorative sleep quality associated with memory consolidation and neuroplasticity.
→ View study

GABA and sleep-wake regulation (2024 review — PMC)
A review confirmed that GABAergic activity in the hypothalamus is central to regulating the sleep-wake cycle, contextualizing why muscimol’s mechanism is so directly relevant to sleep support.
→ View study

 

Gaboxadol Phase III clinical trials for insomnia (Roth et al., 2010 — Journal of Clinical Sleep Medicine)

The broader clinical program concluded that muscimol at pharmaceutical doses was too non-selective for drug development, which led researchers to create gaboxadol (THIP), a synthetic muscimol analogue designed to be more selective and better tolerated. Gaboxadol advanced all the way to Phase III clinical trials for insomnia before being shelved in 2007 for commercial rather than safety reasons. 

→ View Study

Worth noting: muscimol and its synthetic analogue gaboxadol both improve slow wave sleep without suppressing REM, which is a meaningful distinction from benzodiazepines and z-drugs that disrupt SWS even as they improve sleep onset.

 

Dreaming

There are no formal studies on muscimol and dreaming specifically, though hundreds of people report vivid and lucid dreaming as one of the most consistent effects of working with Amanita. What we do have is an interesting adjacent study showing that facing fears through lucid dreaming may help overcome phobias, which points to the therapeutic potential of the dream state that Amanita seems to reliably deepen.
→ View study on lucid dreaming and fears

 

Pain

Muscimol and neuropathic pain (Ramawad et al., 2023 — systematic review)
A 2023 systematic review of 22 studies found muscimol effective at reducing neuropathic pain, with effects appearing within 15 minutes and lasting at least three hours. The authors suggest muscimol’s selective binding to GABAa receptor may offer a pathway for targeted pain therapy with fewer side effects than existing pharmaceutical options.

→ View study

 

Amanita polysaccharides and inflammatory pain (Ruthes et al., 2013 — Carbohydrate Polymers)
Polysaccharide compounds isolated from Amanita muscaria showed potent inhibition of inflammatory pain in animal models, suggesting the full mushroom contains active anti-inflammatory compounds beyond muscimol alone.
→ View study

Muscimol and systemic inflammation (2022 animal study)
Muscimol was shown to protect against systemic inflammatory responses in animal models, adding to evidence of a broader anti-inflammatory profile.

→ View study

 

Brain Health & Neuroprotection

Amanita muscaria extract and neuroprotection (Dushkov et al., 2019 — Food and Chemical Toxicology)
A standardized muscimol-rich Amanita extract showed statistically significant neuroprotective effects across multiple in vitro neurotoxicity models, including antioxidant and free radical scavenging activity.
→ View study

Muscimol and Alzheimer’s disease (Fu et al. / PubMed, 2018)
Very low doses of muscimol improved spatial memory and reduced neuroinflammatory markers in rat Alzheimer’s models, normalizing GABA synthesis enzymes and reducing acetylcholine breakdown, two pathways disrupted in the disease.
→ View study

Muscimol and Parkinson’s disease (Levy et al., 1999 — Neurology)
Muscimol microinjections into the subthalamic nucleus reversed Parkinsonian motor symptoms in a small human study, one of the few direct human applications of muscimol in a clinical context.
→ View study

Muscimol and essential tremors (Gironell et al., 2019 — Tremor and Other Hyperkinetic Movements)
Multiple studies found muscimol suppressed essential tremor without impairing speech or coordination via its inhibitory effects on cerebellar and thalamic circuits involved in tremor generation.
→ View overview

Muscimol and stroke / cerebral ischemia (Lyden & Lonzo, 1994; Bhatt et al., 1993)
Multiple studies through the 1990s established muscimol as neuroprotective in stroke models, protecting the cortex, hippocampus, striatum, thalamus, and substantia nigra from ischemic damage. Combining muscimol with an NMDA antagonist produced enhanced protection compared to either alone, addressing both arms of the excitotoxic cascade that causes neuronal death after stroke.
→ View study

Amanita muscaria and neuroinflammation (Wagner et al., 2023 — Frontiers in Pharmacology)
The first study to examine Amanita extract’s effect on human microglia, the brain’s resident immune cells. The authors note that the whole mushroom’s chemical complexity produces effects beyond muscimol alone, which supports the whole-mushroom argument over synthetic isolates.
→ View study

 

Oral muscimol in Huntington’s disease (Shoulson et al., 1978 — Annals of Neurology)
Ten patients received oral muscimol in a double-blind trial. Overall motor and cognitive improvement was not observed, but chorea was meaningfully reduced in the most severely affected patient. Notable as one of the only double-blind trials in which muscimol was administered orally to humans, confirming blood-brain barrier penetration and central GABAergic effects at oral doses.
→ View study

 

Mood

Muscimol and serotonin (König-Bersin et al., 1970 — Psychopharmacologia)
Muscimol increased serotonin concentrations in the brain while reducing catecholamines like epinephrine and norepinephrine, consistent with mood stabilization and nervous system calming.
→ View study

Muscimol and dopamine (PubMed, 1981)
At low doses, muscimol modulates dopamine activity in the brain’s reward circuits, relevant to motivation, presence, and sense of wellbeing.
→ View study

 

Epilepsy

Muscimol and anticonvulsant activity (Dray & Straughan, 1976 — Neuropharmacology)
Muscimol demonstrated anticonvulsant effects in rat seizure models, delaying onset of convulsions and abolishing tonic extension in several seizure types. Potency ranked as diazepam > muscimol > phenobarbital > phenytoin.
→ View study

Phase 1 human clinical trial for drug-resistant epilepsy (Heiss et al., 2019 — Neurosurgery / NIH)
An NIH-funded trial delivered muscimol directly into epileptic brain tissue in patients with drug-resistant epilepsy, establishing 24-hour safety in humans and observing seizure reduction in one of three patients. The most rigorous direct human study of muscimol to date.
→ View study

 

Addiction & Substance Use

Muscimol and cocaine self-administration (Asin & Wirtshafter, 1985)
Animal studies found muscimol reduced cocaine self-administration in rats via its inhibitory effect on the ventral tegmental area and downstream modulation of dopamine in the nucleus accumbens, the brain’s central reward circuit.

→ View study

Muscimol and nicotine dependence (Corrigall et al., 2000 — Psychopharmacology)
GABA agonists including muscimol substantially reduced nicotine self-administration in rats when delivered into the VTA, more effectively than they reduced cocaine self-administration in the same model. This suggests GABAergic modulation is a particularly important lever for nicotine addiction specifically.
→ View study

Large-Scale Observational Research

Microdosing with Amanita Muscaria (Baba Masha, 2022)
A two-year observational study with 5,900 participants documented self-reported outcomes from Amanita microdosing. Key findings: 92% reported positive overall outcomes, 79% reported improvement in depression and low energy, 73% reported improved sleep, and 88% reported increased energy and vitality. Not a controlled clinical trial, but the largest human dataset on Amanita microdosing that exists.

I break down all the results of this study in the blog post "Summary of Baba Masha’s Book: Microdosing Amanita Muscaria?"

Peer-reviewed microdosing case study (Turkia, 2024 — ResearchGate)
A peer-reviewed retrospective case study followed a woman microdosing Amanita for 3.5 months for depression, anxiety, and sleep disorders. All symptoms reduced meaningfully, no adverse effects were reported, and liver function tests showed slight improvement rather than deterioration.
→ View study

Amanita as an Entheogen

The studies on this page explain much of what people experience with Amanita, but not all of it. Many long-term practitioners working with this mushroom view it not as another drug, but as an entheogen: a plant medicine with a spiritual and consciousness-expanding dimension. What makes Amanita unique is the spiritual effects many people notice. Users consistently report having effects that go beyond typical GABAergics (like an increase in intuition, aura strength & confidence) and some receive personalized messages that they feel come from the mushroom spirit itself. This suggests the mushroom most likely has a spiritual component that cannot be ignored. 

These qualities place Amanita beyond what pharmacology alone can explain. The science here is a meaningful starting point, but science alone can only explain what we can measure. Much of the universe exists beyond our physical senses and Amanita muscaria is no exception.

-----

Last updated: 2026. 

Know of research I missed? Reach out at tara@luminita.co